Disposition of 1599417 shares by Column Group Ii, Lp of RAPT Therapeutics at 1.0E-4 subject to Rule 16b-3
Slightly above 67% of RAPT Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding RAPT Therapeutics suggests that many traders are alarmed. RAPT Therapeutics' investing sentiment can be driven by a variety of factors including economic data, RAPT Therapeutics' earnings reports, geopolitical events, and overall market trends.
RAPT |
Filed transaction by RAPT Therapeutics Other: Former 10% Owner. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at bizjournals.com
 |
RAPT Therapeutics Fundamental Analysis
We analyze RAPT Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of RAPT Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of RAPT Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
RAPT Therapeutics is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
RAPT Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with RAPT Therapeutics stock to make a market-neutral strategy. Peer analysis of RAPT Therapeutics could also be used in its relative valuation, which is a method of valuing RAPT Therapeutics by comparing valuation metrics with similar companies.
Peers
RAPT Therapeutics Related Equities
| ANEB | Anebulo Pharmaceuticals | 26.26 | ||||
| ANTX | AN2 Therapeutics | 11.11 | ||||
| IKNA | Ikena Oncology | 7.74 | ||||
| PEPG | PepGen | 7.16 | ||||
| MOLN | Molecular Partners | 7.09 | ||||
| CNTB | Connect Biopharma | 6.32 | ||||
| MLYS | Mineralys Therapeutics, | 4.81 | ||||
| RLAY | Relay Therapeutics | 4.33 | ||||
| ARVN | Arvinas | 4.06 | ||||
| DSGN | Design Therapeutics | 2.25 | ||||
| PLRX | Pliant Therapeutics | 0.98 | ||||
| PMVP | Pmv Pharmaceuticals | 0.67 | ||||
| STOK | Stoke Therapeutics | 0.60 | ||||
| TYRA | Tyra Biosciences | 1.12 | ||||
| HOWL | Werewolf Therapeutics | 1.26 | ||||
| GLUE | Monte Rosa | 1.26 | ||||
| BDTX | Black Diamond | 1.35 | ||||
| PHVS | Pharvaris | 3.27 | ||||
| HCWB | HCW Biologics | 11.11 | ||||
| XLO | Xilio Development | 13.28 |
Additional Tools for RAPT Stock Analysis
When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.